Deepdive – Research and Development

While we should be hesitant in saying the COVID-19 pandemic will be over soon (I think we were all saying that last spring, after all) there is at least some light at the end of the tunnel, thanks primarily to pharma’s historic R&D efforts in new drugs and vaccines.

It seems like a good time, then, for the industry to start doing what it was unable to do at the outset of COVID-19 – planning for the future to ensure the R&D landscape can remain as strong as it is now.

As we find out in this issue, achieving this will require the industry to harness agile working, digitalisation and new, collaborative infrastructures.